• In late June 2026, Immunome, Inc. was removed from several Russell indices, including the Russell Microcap, Microcap Growth, and Russell 3000E benchmarks.
• This index removal coincided with insider stock sales and a Form 144 filing, drawing extra attention to Immunome’s shareholder base and trading liquidity.
• With Immunome dropped from multiple Russell indices, we’ll explore how this reshapes the company’s investment narrative over the coming weeks.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Immunome's Investment Narrative?

To own Immunome today, you have to believe that its antibody-drug conjugate and varegacestat programs can justify years of losses and minimal current revenue, even as the share price has already moved sharply over the past year. The latest Russell index removals, coupled with a Form 144 and insider sales under a 10b5-1 plan, mostly affect who owns the stock and how it trades rather than near term clinical catalysts like the IM-1617 Phase 1 readouts or the varegacestat regulatory path. That said, forced selling by index funds and a thinner institutional base can make funding the pipeline more sensitive to market swings, on top of existing risks around ongoing dilution, a US$224.59 million annual loss and no clear path to profitability.

However, one risk that is easy to underestimate is how future funding needs might hit existing holders. Immunome's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$35 to over US$180 per share, showing how far apart expectations can be. You are seeing that disagreement just as index removals, insider sales and persistent losses keep execution and funding risk front and center for Immunome’s next phase.

Explore 2 other fair value estimates on Immunome - why the stock might be worth over 8x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 41 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.